OncoMatch

OncoMatch/Clinical Trials/NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Is NCT05581004 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including RO7502175 and Atezolizumab for locally advanced or metastatic solid tumors.

Phase 1RecruitingGenentech, Inc.NCT05581004Data as of May 2026

Treatment: RO7502175 · Atezolizumab · Pembrolizumab — This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Non-Small Cell Lung Carcinoma

Head and Neck Squamous Cell Carcinoma

Melanoma

Triple-Negative Breast Cancer

Esophageal Carcinoma

Gastric Cancer

Cervical Cancer

Colorectal Cancer

Urothelial Carcinoma

Renal Cell Carcinoma

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: any anti-cancer therapy

Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Stanford University · San Francisco, California
  • University Of Colorado · Aurora, Colorado
  • Florida Cancer Specialists - Sarasota · Sarasota, Florida
  • Winship Cancer Institute · Atlanta, Georgia
  • Dana Farber Cancer Institute · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify